Rani Therapeutics gets 180-day Nasdaq compliance extension

Available on EDGAR 11/12/2026 - 04:21 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. transferred its Class A common stock listing from The Nasdaq Global Market to The Nasdaq Capital Market effective November 12, 2026, and received an additional 180 calendar days, through May 10, 2027, to regain compliance with Nasdaq’s $1.00 minimum bid-price requirement. The stock continues to trade under the symbol RANI.

To regain compliance, the closing bid price must be at least $1.00 per share for at least 10 consecutive business days. Nasdaq may require a longer period, generally not exceeding 20 consecutive business days. Rani said it would monitor the price and evaluate options, including a reverse stock split if necessary, but there is no assurance it will regain compliance or maintain compliance with other continued listing requirements.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Minimum closing bid price: $1.00 per share Additional compliance period: 180 calendar days Required consecutive compliance period: 10 consecutive business days +1 more

4 metrics

Minimum closing bid price $1.00 per share Nasdaq’s Minimum Bid Price Requirement

Additional compliance period 180 calendar days Granted through May 10, 2027

Required consecutive compliance period 10 consecutive business days Minimum period at or above the required closing bid price

Possible extended compliance period Generally not exceeding 20 consecutive business days Nasdaq may require a longer period before determining compliance

Key Terms

Minimum Bid Price Requirement, market value of publicly held shares requirement, continued listing requirements

3 terms

Minimum Bid Price Requirement regulatory

"regain compliance with the Minimum Bid Price Requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

market value of publicly held shares requirement regulatory

"met the applicable market value of publicly held shares requirement"

A regulatory threshold that requires a company to have a minimum market value of shares held by public investors (public float) to qualify for listing or to remain on a stock exchange. It matters to investors because it affects a stock's eligibility for trading venues and indexes and signals liquidity and public ownership levels—similar to a minimum crowd size needed for an event to run smoothly, it influences how easily shares can be bought or sold.

continued listing requirements regulatory

"other continued listing requirements of The Nasdaq Capital Market"

Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does RANI need to do to meet Nasdaq’s minimum bid-price requirement?

RANI’s closing bid price must be at least $1.00 per share for at least 10 consecutive business days. Nasdaq may require a longer period, generally not exceeding 20 consecutive business days. If RANI regains compliance, Nasdaq will provide written confirmation and close the matter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001856725false00018567252026-11-102026-11-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2026

Rani Therapeutics Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40672	86-3114789
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
47709 Fremont Blvd
Fremont, California				94538
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (408) 457-3700

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, par value $0.0001 per share		RANI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on May 11, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s Class A common stock for the preceding 30 consecutive business days, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1), which requires listed securities to maintain a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The Company was initially provided 180 calendar days, or until November 9, 2026, to regain compliance with the Minimum Bid Price Requirement.

On November 10, 2026, the Company received written notice from Nasdaq notifying the Company that it had approved the Company’s application to transfer the listing of its Class A common stock from The Nasdaq Global Market to The Nasdaq Capital Market and had granted the Company an additional 180 calendar days, or until May 10, 2027, to regain compliance with the Minimum Bid Price Requirement. The transfer to The Nasdaq Capital Market was effective at the opening of business on November 12, 2026. The Company’s Class A common stock will continue to trade under the symbol “RANI.”

According to the notice, the Company was eligible for the additional compliance period because it met the applicable market value of publicly held shares requirement for continued listing and all other applicable requirements for initial listing on The Nasdaq Capital Market, other than the Minimum Bid Price Requirement, and provided written notice of its intention to cure the deficiency, including by effecting a reverse stock split, if necessary.

To regain compliance with the Minimum Bid Price Requirement, the closing bid price of the Company’s Class A common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time during the additional 180-day compliance period. Nasdaq may, in its discretion, require the Company to maintain a closing bid price of at least $1.00 per share for a longer period, generally not exceeding 20 consecutive business days, before determining that the Company has regained compliance. If the Company regains compliance with the Minimum Bid Price Requirement, Nasdaq will provide the Company with written confirmation of compliance and will close the matter.

The Company intends to actively monitor the closing bid price of its Class A common stock and will evaluate available options to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will regain compliance with the Minimum Bid Price Requirement during the additional compliance period or otherwise maintain compliance with the other continued listing requirements of The Nasdaq Capital Market.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Rani Therapeutics Holdings, Inc.
Date:	November 12, 2026	By:	/s/ Nicholas M. Maestas
			Nicholas M. Maestas Chief Financial Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.3 KB